ASCO 2017: ipi + pembro, ipi after pembro, tumor response and pembro

› Forums › General Melanoma Community › ASCO 2017: ipi + pembro, ipi after pembro, tumor response and pembro

  • Post
Viewing 0 reply threads
  • Replies
      • June 21, 2017 at 5:39 pm
      ed williams
      Participant

        Hi Celeste, I would have to agree with you about the pembro + Ipi trial, why can't big pharma do things the same so that you can compare!!! My best guess is Merck is trying to get the business away from BMS so they had to do something different and less drug means less cost to Insurance companies and Governments. In Ontario, Canada they picked Keytruda over nivo for stage 4 folks , same reason $$$ plus they also save on Oncologist visit once every three weeks vs once every two weeks. I always find it interesting as well when you take a deeper look at the patient population, 75% of Pembr + Ipi trial had non elevated LDH!!! I wonder if they will have to do a larger study or will they get approvals based on this small sample size?  Best Wishes!!! Ed

          • June 22, 2017 at 3:19 pm
          Bubbles
          Participant

            It all gets 'curiouser and curiouser', doesn't it, Edster????   c

      Viewing 0 reply threads
      • You must be logged in to reply to this topic.
      About the MRF Patient Forum

      The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

      The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.